Istanbul Okan University
Istanbul, 34959, Turkey (Türkiye)
NCT Number: NCT04412278
It is aimed to determine the physical activity level and exercise benefits and barriers caused by Covid-19 pandemic and reveal the relationship between them.
Looking for future studies?
Notify Me15 year–65 year
All sexes
Observational
Istanbul, 34959, Turkey (Türkiye)
Study hypothesis that people are tend to be physically inactive while Covid-19 pandemic. It is aimed to determine the exercise benefits and barriers caused by Covid-19 pandemic and reveal the relationship among gender, age, marial status and physical activity level.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
Time frame: three months after Covid 19 recognised as pandemic
The Exercise Benefits/Barriers Scale (EBBS) was developed in response to a need for an instrument to determine perceptions of individuals concerning the benefits of and barriers to participating in exercise. The instrument may be scored and used in its entirety or as two separate scales. The instrument has a four-response, forced-choice Likert-type format with responses ranging from 4 (strongly agree) to 1 (strongly disagree). Scores on the total instrument can range from 43 to 172. The higher the score, the more positively the individual perceives exercise. When the Benefits Scale is used alone, the score range is between 29 and 116. When the Barriers Scale is used alone, scores range between 14 and 56. If used alone, the Barriers Scale does not need to be reverse-scored. In this instance, the higher the score on the Barriers Scale, the greater the perception of barriers to exercise.
Time frame: three months after Covid 19 recognised as pandemic
Participants will be asked to give information about: age, gender, educational status, height, weight, occupation, working status, whether they have a chronic disease.
Time frame: three months after Covid 19 recognised as pandemic
The IPAQ-S developed for participants to report activities performed for at least 10 minutes during the last 7 days. Respondents will be asked to report time spent in physical activity performed across leisure time, work, domestic activities, and transport at each of 3 intensities: walking, moderate, and vigorous. Using the instrument's scoring protocol total weekly physical activity was estimated by weighting time spent in each activity intensity with its estimated metabolic equivalent (MET) energy expenditure. The IPAQ scoring protocol assigns the following MET values to walking, moderate, and vigorous intensity activity: 3.3 METs, 4.0 METs, and 8.0 METs, respectively. Participants will be considered to have met American Collage of Sports Medicine physical activity recommendations. if they reported at least 150 min/wk of walking, moderate, or vigorous intensity physical activity.
Okan University
Other
Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers: Cross Sectional Study on Turkish Society and Interpretation With Physical Activity Level
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06821139
COVID, COVID - 19
Surrey, British Columbia, Canada
View Trial DetailsNCT04407143
COVID, COVID-19
A Coruña, Spain
View Trial DetailsNCT04394390
Avitaminosis, COVID
Bursa, Dogankoy, Turkey (Türkiye)
View Trial DetailsNCT04395599
COVID, COVID-19
Lille, France
View Trial Details